Cargando…

How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide with no specific treatment. Weight loss is the most effective therapeutic strategy in its management; however, there is no consensus on its specifics. Thus, this study was conducted to evaluate the effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghaemi, Alireza, Taleban, Fourugh Azam, Hekmatdoost, Azita, Rafiei, Alireza, Hosseini, Vahid, Amiri, Zohreh, Homayounfar, Reza, Fakheri, Hafez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867211/
https://www.ncbi.nlm.nih.gov/pubmed/24358045
http://dx.doi.org/10.5812/hepatmon.15227
_version_ 1782296267293982720
author Ghaemi, Alireza
Taleban, Fourugh Azam
Hekmatdoost, Azita
Rafiei, Alireza
Hosseini, Vahid
Amiri, Zohreh
Homayounfar, Reza
Fakheri, Hafez
author_facet Ghaemi, Alireza
Taleban, Fourugh Azam
Hekmatdoost, Azita
Rafiei, Alireza
Hosseini, Vahid
Amiri, Zohreh
Homayounfar, Reza
Fakheri, Hafez
author_sort Ghaemi, Alireza
collection PubMed
description BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide with no specific treatment. Weight loss is the most effective therapeutic strategy in its management; however, there is no consensus on its specifics. Thus, this study was conducted to evaluate the effects of weight loss on liver enzymes, markers of inflammation, oxidative stress and CK18-M30 (cytokeratin 18) as a biomarker of hepatocellular apoptosis. OBJECTIVES: To study the effect of weight reduction diet as an exclusive treatment for NAFLD. PATIENTS AND METHODS: Forty four patients with NAFLD received a diet including a 500 to 1000 kcal per day intake reduction as30% fat, 15% protein, and 55% carbohydrate for six months. Anthropometric parameters, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), lipid profile, malondialdehyde (MDA), TNF-α, IL-6, CK18-M30 were measured at baseline and at the end of the study. At the end of follow up, patients were classified as adherent or nonadherent to treatment according to a weight loss of ≥ 5%, or < 5% of initial body weight, respectively. RESULTS: Twenty five patients were classified as adherent group and nineteen as nonadherent group (9.7% vs. 1.9% total body weight loss after 6 months, respectively). After 6 months, changes in adherent and nonadherent groups were as follows: reduction in body weight from 93.7 ± 15.8 kg to 84.2 ± 13.4 kg vs. 94 ± 16.6 kg to 92.2 ± 16.2 kg (P < 0.05), BMI from 32.7 ± 3.9 to 29.5 ± 3.2 vs.31.8 ± 5.4 to 31.1 ± 5.3 (P < 0.001), and waist circumference from 105.1 ± 12.6 cm to 97.4 ± 9.8 cm vs.106.8 ± 14.2 cm to 103.7 ± 14 cm (P < 0.001), respectively. Diastolic blood pressure was significantly decreased in adherent group (from 80.2 ± 5.1 mmHg to 76.9 ± 5 mmHg; P < 0.001). Also, total cholesterol, LDL, triglyceride, ALT, AST, GGT and CK18-M30 levels were significantly decreased in the adherent group compared to nonadherent group (P < 0.05). CONCLUSIONS: This intervention offers a practical approach for treatment of patients with NAFLD with diet therapy.
format Online
Article
Text
id pubmed-3867211
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-38672112013-12-19 How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease? Ghaemi, Alireza Taleban, Fourugh Azam Hekmatdoost, Azita Rafiei, Alireza Hosseini, Vahid Amiri, Zohreh Homayounfar, Reza Fakheri, Hafez Hepat Mon Research Article BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide with no specific treatment. Weight loss is the most effective therapeutic strategy in its management; however, there is no consensus on its specifics. Thus, this study was conducted to evaluate the effects of weight loss on liver enzymes, markers of inflammation, oxidative stress and CK18-M30 (cytokeratin 18) as a biomarker of hepatocellular apoptosis. OBJECTIVES: To study the effect of weight reduction diet as an exclusive treatment for NAFLD. PATIENTS AND METHODS: Forty four patients with NAFLD received a diet including a 500 to 1000 kcal per day intake reduction as30% fat, 15% protein, and 55% carbohydrate for six months. Anthropometric parameters, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), lipid profile, malondialdehyde (MDA), TNF-α, IL-6, CK18-M30 were measured at baseline and at the end of the study. At the end of follow up, patients were classified as adherent or nonadherent to treatment according to a weight loss of ≥ 5%, or < 5% of initial body weight, respectively. RESULTS: Twenty five patients were classified as adherent group and nineteen as nonadherent group (9.7% vs. 1.9% total body weight loss after 6 months, respectively). After 6 months, changes in adherent and nonadherent groups were as follows: reduction in body weight from 93.7 ± 15.8 kg to 84.2 ± 13.4 kg vs. 94 ± 16.6 kg to 92.2 ± 16.2 kg (P < 0.05), BMI from 32.7 ± 3.9 to 29.5 ± 3.2 vs.31.8 ± 5.4 to 31.1 ± 5.3 (P < 0.001), and waist circumference from 105.1 ± 12.6 cm to 97.4 ± 9.8 cm vs.106.8 ± 14.2 cm to 103.7 ± 14 cm (P < 0.001), respectively. Diastolic blood pressure was significantly decreased in adherent group (from 80.2 ± 5.1 mmHg to 76.9 ± 5 mmHg; P < 0.001). Also, total cholesterol, LDL, triglyceride, ALT, AST, GGT and CK18-M30 levels were significantly decreased in the adherent group compared to nonadherent group (P < 0.05). CONCLUSIONS: This intervention offers a practical approach for treatment of patients with NAFLD with diet therapy. Kowsar 2013-12-07 /pmc/articles/PMC3867211/ /pubmed/24358045 http://dx.doi.org/10.5812/hepatmon.15227 Text en Copyright © 2013, Kowsar Corp. http://creativecommons.org/licenses/by/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ghaemi, Alireza
Taleban, Fourugh Azam
Hekmatdoost, Azita
Rafiei, Alireza
Hosseini, Vahid
Amiri, Zohreh
Homayounfar, Reza
Fakheri, Hafez
How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?
title How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?
title_full How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?
title_fullStr How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?
title_full_unstemmed How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?
title_short How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?
title_sort how much weight loss is effective on nonalcoholic fatty liver disease?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867211/
https://www.ncbi.nlm.nih.gov/pubmed/24358045
http://dx.doi.org/10.5812/hepatmon.15227
work_keys_str_mv AT ghaemialireza howmuchweightlossiseffectiveonnonalcoholicfattyliverdisease
AT talebanfourughazam howmuchweightlossiseffectiveonnonalcoholicfattyliverdisease
AT hekmatdoostazita howmuchweightlossiseffectiveonnonalcoholicfattyliverdisease
AT rafieialireza howmuchweightlossiseffectiveonnonalcoholicfattyliverdisease
AT hosseinivahid howmuchweightlossiseffectiveonnonalcoholicfattyliverdisease
AT amirizohreh howmuchweightlossiseffectiveonnonalcoholicfattyliverdisease
AT homayounfarreza howmuchweightlossiseffectiveonnonalcoholicfattyliverdisease
AT fakherihafez howmuchweightlossiseffectiveonnonalcoholicfattyliverdisease